The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.
Lawrence N. Shulman
No relevant relationships to disclose
Donald A. Berry
Employment or Leadership Position - Berry Consultants
Consultant or Advisory Role - Berry Consultants
Constance T. Cirrincione
No relevant relationships to disclose
Heather Becker
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose
Ruth O'Regan
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
Charles L. Shapiro
No relevant relationships to disclose
James Atkins
No relevant relationships to disclose
Charles Schneider
No relevant relationships to disclose
Gretchen Genevieve Kimmick
Honoraria - CHAMBER Foundation
Research Funding - Bionovo; Bristol-Myers Squibb; GlaxoSmithKline; Wyeth
Other Remuneration - AstraZeneca; Genomic Health; Novartis; Pfizer
Harold J. Burstein
No relevant relationships to disclose
Larry Norton
No relevant relationships to disclose
Hyman Bernard Muss
Consultant or Advisory Role - Pfizer
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)
Eric P. Winer
No relevant relationships to disclose